1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Real-time Estimate Cboe BZX  -  05/26 03:52:06 pm EDT
204.88 USD   +1.25%
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BofA Securities Adjusts Biogen's Price Target to $245 From $275, Maintains Neutral Rating

01/14/2022 | 10:54am EDT


© MT Newswires 2022
All news about BIOGEN INC.
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 838 M - -
Net income 2022 1 996 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 14,4x
Yield 2022 -
Capitalization 29 636 M 29 636 M -
EV / Sales 2022 3,01x
EV / Sales 2023 2,81x
Nbr of Employees 9 610
Free-Float 85,4%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 202,36 $
Average target price 245,86 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-15.66%29 636
CSL LIMITED-5.89%93 252
SAMSUNG BIOLOGICS CO.,LTD.-6.98%46 658
WUXI BIOLOGICS (CAYMAN) INC.-42.41%28 644
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.66%21 435
UCB-17.63%16 697